Stock Analysis on Net

DexCom Inc. (NASDAQ:DXCM)

This company has been moved to the archive! The financial data has not been updated since October 26, 2023.

Common Stock Valuation Ratios (Price Multiples) 

Microsoft Excel

Current Valuation Ratios

DexCom Inc., current price multiples

Microsoft Excel
DexCom Inc. Abbott Laboratories Cigna Group CVS Health Corp. Danaher Corp. Elevance Health Inc. Humana Inc. Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc. Health Care Equipment & Services Health Care
Selected Financial Data
Current share price (P) $81.09
No. shares of common stock outstanding 386,373,935
Growth rate (g) 10.22%
 
Earnings per share (EPS) $0.88
Next year expected EPS $0.97
Operating profit per share $1.01
Sales per share $7.53
Book value per share (BVPS) $5.52
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 91.83 35.96 18.85 11.14 39.90 19.40 17.06 77.97 29.54 20.17 24.04 23.83
Price to next year expected earnings 83.31 33.65 16.93 10.49 36.41 17.24 14.53 68.70 28.95 17.20 21.80 21.48
Price-earnings-growth (PEG) 8.98 5.24 1.66 1.82 4.16 1.55 0.98 5.78 14.43 1.17 2.34 2.18
Price to operating profit (P/OP) 80.09 31.77 11.40 6.76 36.38 15.25 10.58 79.35 20.24 13.95 17.98 18.48
Price to sales (P/S) 10.77 5.13 0.50 0.26 7.92 0.68 0.40 19.68 3.55 1.23 1.22 2.46
Price to book value (P/BV) 14.70 5.33 2.11 1.22 3.54 2.95 2.61 10.53 2.16 5.08 3.66 5.33

Based on: 10-K (reporting date: 2022-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

DexCom Inc., historical price multiples

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Price to earnings (P/E) 121.45 255.37 79.93 228.49
Price to operating profit (P/OP) 105.93 148.63 131.73 162.33
Price to sales (P/S) 14.24 16.13 20.48 15.65 12.76
Price to book value (P/BV) 19.44 17.55 21.60 26.17 19.84

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. DexCom Inc. P/E ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. DexCom Inc. P/OP ratio increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. DexCom Inc. P/S ratio decreased from 2020 to 2021 and from 2021 to 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. DexCom Inc. P/BV ratio decreased from 2020 to 2021 but then slightly increased from 2021 to 2022.

Price to Earnings (P/E)

DexCom Inc., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 386,413,690 388,262,536 384,709,452 366,376,568 360,007,068
Selected Financial Data (US$)
Net income (loss) (in thousands) 341,200 154,700 493,600 101,100 (127,100)
Earnings per share (EPS)2 0.88 0.40 1.28 0.28 -0.35
Share price1, 3 107.24 101.75 102.55 63.05 36.56
Valuation Ratio
P/E ratio4 121.45 255.37 79.93 228.49
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 26.76 29.13 48.49 41.83
Cigna Group 13.13 13.43 8.71 13.26
CVS Health Corp. 27.53 17.39 12.88 14.15
Danaher Corp. 25.65 29.94 44.49 38.34
Elevance Health Inc. 19.20 18.13 15.87 15.96
Humana Inc. 22.52 18.34 14.48 18.10
Intuitive Surgical Inc. 64.99 59.94 87.47 48.72
Medtronic PLC 23.38 46.56 26.30 28.78 37.80
UnitedHealth Group Inc. 22.46 26.03 20.54 20.48
P/E Ratio, Sector
Health Care Equipment & Services 23.33 25.54 22.65 22.70
P/E Ratio, Industry
Health Care 21.08 21.04 28.47 21.23

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
EPS = Net income (loss) ÷ No. shares of common stock outstanding
= 341,200,000 ÷ 386,413,690 = 0.88

3 Closing price as at the filing date of DexCom Inc. Annual Report.

4 2022 Calculation
P/E ratio = Share price ÷ EPS
= 107.24 ÷ 0.88 = 121.45

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. DexCom Inc. P/E ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.

Price to Operating Profit (P/OP)

DexCom Inc., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 386,413,690 388,262,536 384,709,452 366,376,568 360,007,068
Selected Financial Data (US$)
Operating income (loss) (in thousands) 391,200 265,800 299,500 142,300 (186,300)
Operating profit per share2 1.01 0.68 0.78 0.39 -0.52
Share price1, 3 107.24 101.75 102.55 63.05 36.56
Valuation Ratio
P/OP ratio4 105.93 148.63 131.73 162.33
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 22.18 24.45 40.69 34.03
Cigna Group 10.40 9.08 9.03 8.38
CVS Health Corp. 14.75 10.43 6.65 7.83
Danaher Corp. 20.97 25.14 36.91 34.47
Elevance Health Inc. 15.05 15.70 12.10 13.55
Humana Inc. 16.63 17.08 9.78 15.35
Intuitive Surgical Inc. 54.49 56.11 88.37 48.89
Medtronic PLC 20.48 37.44 26.29 21.26 17.64
UnitedHealth Group Inc. 15.89 18.77 14.12 14.40
P/OP Ratio, Sector
Health Care Equipment & Services 17.45 19.20 16.88 16.21
P/OP Ratio, Industry
Health Care 16.35 17.40 21.24 17.43

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= 391,200,000 ÷ 386,413,690 = 1.01

3 Closing price as at the filing date of DexCom Inc. Annual Report.

4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 107.24 ÷ 1.01 = 105.93

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. DexCom Inc. P/OP ratio increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.

Price to Sales (P/S)

DexCom Inc., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 386,413,690 388,262,536 384,709,452 366,376,568 360,007,068
Selected Financial Data (US$)
Revenue (in thousands) 2,909,800 2,448,500 1,926,700 1,476,000 1,031,600
Sales per share2 7.53 6.31 5.01 4.03 2.87
Share price1, 3 107.24 101.75 102.55 63.05 36.56
Valuation Ratio
P/S ratio4 14.24 16.13 20.48 15.65 12.76
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.25 4.78 6.30 4.83
Cigna Group 0.49 0.42 0.46 0.44
CVS Health Corp. 0.36 0.47 0.35 0.37
Danaher Corp. 5.79 6.37 7.01 6.29
Elevance Health Inc. 0.74 0.81 0.60 0.74
Humana Inc. 0.68 0.65 0.64 0.76
Intuitive Surgical Inc. 13.81 17.89 21.29 15.01
Medtronic PLC 3.72 5.57 4.36 4.36 3.92
UnitedHealth Group Inc. 1.40 1.58 1.24 1.18
P/S Ratio, Sector
Health Care Equipment & Services 1.19 1.38 1.23 1.15
P/S Ratio, Industry
Health Care 2.17 2.29 2.24 2.16

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Sales per share = Revenue ÷ No. shares of common stock outstanding
= 2,909,800,000 ÷ 386,413,690 = 7.53

3 Closing price as at the filing date of DexCom Inc. Annual Report.

4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 107.24 ÷ 7.53 = 14.24

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. DexCom Inc. P/S ratio decreased from 2020 to 2021 and from 2021 to 2022.

Price to Book Value (P/BV)

DexCom Inc., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 386,413,690 388,262,536 384,709,452 366,376,568 360,007,068
Selected Financial Data (US$)
Stockholders’ equity (in thousands) 2,131,800 2,251,500 1,826,500 882,600 663,300
Book value per share (BVPS)2 5.52 5.80 4.75 2.41 1.84
Share price1, 3 107.24 101.75 102.55 63.05 36.56
Valuation Ratio
P/BV ratio4 19.44 17.55 21.60 26.17 19.84
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.06 5.75 6.65 4.96
Cigna Group 1.95 1.53 1.46 1.49
CVS Health Corp. 1.61 1.83 1.33 1.47
Danaher Corp. 3.64 4.16 3.93 3.72
Elevance Health Inc. 3.19 3.07 2.19 2.42
Humana Inc. 4.13 3.34 3.55 4.07
Intuitive Surgical Inc. 7.78 8.59 9.53 8.13
Medtronic PLC 2.24 3.26 2.48 2.66 2.31
UnitedHealth Group Inc. 5.81 6.27 4.83 4.92
P/BV Ratio, Sector
Health Care Equipment & Services 3.55 3.81 3.28 3.14
P/BV Ratio, Industry
Health Care 4.72 4.81 4.61 4.46

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 2,131,800,000 ÷ 386,413,690 = 5.52

3 Closing price as at the filing date of DexCom Inc. Annual Report.

4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 107.24 ÷ 5.52 = 19.44

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. DexCom Inc. P/BV ratio decreased from 2020 to 2021 but then slightly increased from 2021 to 2022.